Merck & Co.’ Inc.’s stock MRK rose 2% premarket Tuesday, after the company reported positive results for a new formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck said a ...
The Rebecca Foundation, in collaboration with Merck Foundation, has presented 30 brilliant but needy girls with school ...
In a significant move towards the liberalization of the healthcare sector, Shanghai's Pudong New Area witnessed the first ...
The pathology and radiology giant is recovering from its post-pandemic malaise and says earnings should improve this year ...
Within 10 years of Crohn's disease diagnosis, up to 50% of people will require surgery, with ileocaecal or ileocolonic resection being the most common procedure.1 Surgery is not curative and disease ...
We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this article, we are going to take a ...
Forget milk — a recent study finds the key to building strong bones in children is for mothers to keep their vitamin D levels high during pregnancy.
Vanguard High Dividend Yield Index Fund is a strong core holding due to its low expense ratio, consistent dividend growth, ...
Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...
The Dow Jones Industrial Average (DJIA), one of the three main Wall Street benchmarks, succumbed to selling pressure in early ...
The U.S. Food and Drug Administration approved the Keytruda combination in malignant pleural mesothelioma in September. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors ...
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback